Skip to main content
. Author manuscript; available in PMC: 2021 Nov 3.
Published in final edited form as: Regul Toxicol Pharmacol. 2019 Sep 21;109:104480. doi: 10.1016/j.yrtph.2019.104480

Table 3.

The distribution of chemicals and lowest observed adverse effect level (LOAEL) values across guideline testing study types. The rows show the endpoint categories and the columns different type of guideline studies including: acute (ACU), chronic (CHR), developmental (DEV), multigenerational (MGR), neurotoxicity (NEU), other (OTH), reproductive (REP), sub-acute (SAC) and sub-chronic (SUB). Further details about these studies are available in ToxRefDB v2.0.

Endpoint Category ACU CHR DEV DNT MGR NEU OTH REP SAC SUB
Cholinesterase inhibition 65 (123) 10 (10) 17 (20) 16 (17) 2 (2) 49 (69)
Developmental effects 391 (531) 41 (54) 149 (165) 2 (2) 12 (12) 2 (2)
Reproductive effects 5 (5) 297 (405) 37 (42) 146 (163) 1 (1) 2 (2) 41 (53) 13 (16) 26 (32)
Systemic effects 3 (3) 607 (1394) 500 (831) 92 (120) 304 (339) 10 (10) 10 (13) 65 (97) 150 (418) 569 (1099)